Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 8/20 | 0.86 |
| ▸ | HTR7 | P34969 | 3/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.49 |
| ▸ | HTR3B | O95264 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 3/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221254 | 0.93 | ADRB1 (1.00) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL21533600 | 0.87 | ADRB1 (0.65) | ADRB1HTR7CHRNB2CHRNA4HTR3E | |
| SCHEMBL5206787 | 0.85 | ADRB1 (0.63) | ADRB1HTR7CHRNB2CHRNA4HTR3E | |
| SCHEMBL5235956 | 0.85 | ADRB1 (0.63) | ADRB1HTR7CHRNB2CHRNA4HTR3E | |
| SCHEMBL5238705 | 0.85 | ADRB1 (0.63) | ADRB1HTR7CHRNB2CHRNA4HTR3E | |
| SCHEMBL1422991 | 0.83 | ADRB1 (0.81) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL27642375 | 0.83 | ADRB1 (0.81) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL24140572 | 0.83 | ADRB1 (0.68) | ADRB1HTR7 | |
| SCHEMBL3539353 | 0.83 | ADRB1 (0.68) | ADRB1HTR7 | |
| SCHEMBL22818466 | 0.83 | ADRB1 (0.59) | ADRB1HTR7CHRNB2CHRNA4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | ADRB1 241/4885HTR7 3237/4885CHRNB2 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.